---
title: Insights into secondgeneration vaccines
videoId: cwpGBCjpJiU
---

From: [[artedeinvertir]] <br/> 

Bill Gates, identified as one of the world's richest and most powerful individuals, appears to be preparing for a new crisis similar to past experiences by accumulating stocks in companies that produce vaccines <a class="yt-timestamp" data-t="00:00:02">[00:00:02]</a>. This represents a radical shift in his [[bill_gates_investment_strategy_in_vaccine_stocks | investment strategy]] <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>. His portfolio movements and statements are closely followed by millions of investors due to his accurate vision of the future economy and [[stock_opportunities_in_healthcare_and_technology_sectors | stocks]] <a class="yt-timestamp" data-t="01:24:00">[01:24:00]</a>.

## Bill Gates' Vision and Investment Focus

Bill Gates played a significant role during the last crisis, having warned about a likely pandemic and global unpreparedness <a class="yt-timestamp" data-t="00:48:00">[00:48:00]</a>. His deep knowledge of the [[biotechnology_investments_and_financial_risks | biotechnology]] sector also led him to predict which company would first develop a successful vaccine <a class="yt-timestamp" data-t="00:58:00">[00:58:00]</a>.

Recently, his investment portfolio has been made public, indicating preparation for a crisis akin to 2020 <a class="yt-timestamp" data-t="01:34:00">[01:34:00]</a>. He has radically altered his [[bill_gates_investment_strategy_in_vaccine_stocks | investment strategy]], concentrating 70% of his investments in just three companies producing vaccines <a class="yt-timestamp" data-t="01:43:00">[01:43:00]</a>. Many investors are questioning if this new strategy reflects a negative outlook on the ongoing crisis <a class="yt-timestamp" data-t="01:57:00">[01:57:00]</a>.

Bill Gates primarily uses two investment vehicles: a fund for traditional, safer shares, and the portfolio of the Bill and Melinda Gates Foundation <a class="yt-timestamp" data-t="02:35:00">[02:35:00]</a>. It is within the Foundation's portfolio that this new [[bill_gates_investment_strategy_in_vaccine_stocks | investment strategy]] has been implemented <a class="yt-timestamp" data-t="02:46:00">[02:46:00]</a>.

According to a CNN interview, Bill Gates explained that rich countries were not adequately providing quality vaccines to poorer nations <a class="yt-timestamp" data-t="03:27:00">[03:27:00]</a>. He warned that variants are returning to richer countries because the problem is not tackled quickly enough, necessitating the [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] of "second-generation vaccines" <a class="yt-timestamp" data-t="03:38:00">[03:38:00]</a>. These are precisely what he is incorporating into his portfolio <a class="yt-timestamp" data-t="03:50:00">[03:50:00]</a>. He stated that a return to normalcy will only occur with the "next generation of vaccines" <a class="yt-timestamp" data-t="08:58:00">[08:58:00]</a>.

## Key Companies in Second-Generation Vaccine Development

Bill Gates' portfolio now includes three key companies leading the [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] of sophisticated and more effective "second-generation vaccines" <a class="yt-timestamp" data-t="03:03:00">[03:03:00]</a>.

*   **BioNTech (BNTX)**: Listed in the United States under ticker BNTX <a class="yt-timestamp" data-t="05:13:00">[05:13:00]</a>. Bill Gates began investing in BioNTech at the end of 2019, six months before the crisis began <a class="yt-timestamp" data-t="05:22:00">[05:22:00]</a>. His initial investment of $50 million is now valued at over $200 million <a class="yt-timestamp" data-t="05:28:00">[05:28:00]</a>. BioNTech, in collaboration with Pfizer, was the first company to launch an effective vaccine <a class="yt-timestamp" data-t="05:33:00">[05:33:00]</a>. The company forecasts a demand for one million doses annually from 2022 onwards, indicating a potential recurrent business <a class="yt-timestamp" data-t="05:43:00">[05:43:00]</a>. It is estimated to earn over $37 per share this year, trading below 10 times earnings, considered an attractive price for a [[biotechnology_investments_and_financial_risks | biotechnology]] company <a class="yt-timestamp" data-t="06:01:00">[06:01:00]</a>.

*   **CureVac (CVAC)**: A German company listed in the United States under ticker CVAC <a class="yt-timestamp" data-t="06:28:00">[06:28:00]</a>. Bill Gates invested in CureVac in 2015 with $50 million, now valued at over $230 million <a class="yt-timestamp" data-t="06:41:00">[06:41:00]</a>. CureVac is collaborating with large companies like GlaxoSmithKline on the "second generation of vaccines" <a class="yt-timestamp" data-t="06:52:00">[06:52:00]</a>. It is considered a more speculative and volatile investment as it is in the [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] phase, not yet profitable, and heavily reliant on the success of its clinical trials <a class="yt-timestamp" data-t="07:03:00">[07:03:00]</a>.

*   **Vir Biotechnology (VIR)**: Listed in the United States under ticker VIR <a class="yt-timestamp" data-t="07:37:00">[07:37:00]</a>. Bill Gates invested in this highly innovative company in 2019 <a class="yt-timestamp" data-t="07:46:00">[07:46:00]</a>. Vir Biotechnology is [[impact_of_bill_gates_forecasts_on_vaccine_development | developing]] an effective solution against multiple variants, including the Delta variant, with over 82% effectiveness <a class="yt-timestamp" data-t="07:52:00">[07:52:00]</a>. An additional point of interest is its [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] of an inhaled vaccine solution, which could simplify application and encourage wider participation <a class="yt-timestamp" data-t="08:07:00">[08:07:00]</a>. Similar to CureVac, this company is in the [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] phase, not yet profitable, making it a highly speculative and risky, yet potentially high-reward, [[stock_opportunities_in_healthcare_and_technology_sectors | stock]] <a class="yt-timestamp" data-t="08:20:00">[08:20:00]</a>.

## Investment Risks and Rewards in Biotechnology

Investing in [[biotechnology_investments_and_financial_risks | biotechnology]] companies in the [[impact_of_bill_gates_forecasts_on_vaccine_development | development]] phase is inherently risky and volatile, requiring a high level of knowledge to succeed due to the high number of failed clinical trials <a class="yt-timestamp" data-t="04:01:00">[04:01:00]</a>. However, successful ventures can yield significant financial rewards <a class="yt-timestamp" data-t="04:14:00">[04:14:00]</a>.

*   **BioNTech** serves as an example: after its clinical trials were announced as satisfactory, its shares rose from $90 to over $350 <a class="yt-timestamp" data-t="04:25:00">[04:25:00]</a>.
*   **Moderna** also illustrates this potential: positioning itself as a leading company for vaccine [[impact_of_bill_gates_forecasts_on_vaccine_development | development]], its shares increased from $70 to over $400 in less than 12 months <a class="yt-timestamp" data-t="04:38:00">[04:38:00]</a>.

Investing in this sector requires considerable knowledge <a class="yt-timestamp" data-t="07:13:00">[07:13:00]</a>. Bill Gates' statements and investment movements offer clues about which companies are best positioned to develop the next generation of vaccines <a class="yt-timestamp" data-t="09:09:00">[09:09:00]</a>. As these companies [[impact_of_bill_gates_forecasts_on_vaccine_development | develop]] effective solutions, they can generate high returns for shareholders <a class="yt-timestamp" data-t="09:23:00">[09:23:00]</a>.